What's new in pharmaDecember 19, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Kevin Dietsch/Getty Images STAT+ | FDA voucher program has become vehicle for political interference in drug review decisions, staffers say The "Commissioner's National Priority Review Program" is seen as having fast-tracked reviews but at the expense of career scientists' expertise. By Lizzy Lawrence STAT+ | White House unveils largest batch of drug pricing agreements yet Trump administration wants to match U.S. drug prices to peer nations, announces new deals with Amgen, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi. By Daniel Payne and John Wilkerson STAT+ | BioMarin CEO says $4.8 billion Amicus deal will lead to cost savings and revenue growth In a Q&A, Alexander Hardy explains the strategy behind the purchase of another rare disease company: "There's an opportunity to drive rapid value." By Matthew Herper ALEX EDELMAN/AFP via Getty Images STAT+ | Opinion: I'm the former head of Pfizer R&D. I'm very worried about biopharma's future Changes at the FDA are going to have a profound impact on drug development, hurting both patients and the industry. By John L. LaMattina STAT+ | U.K.'s state-owned investment bank shows up in the U.S., eager to spend on biotech The British Business Bank has billions to put into life sciences VC firms and startups, as well as other key sectors. By Allison DeAngelis More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments